Early-stage biotechs with limited funds must balance the need for quick data with building a solid IND package. The solution is to run two tracks in parallel: one for immediate R&D experiments and another dedicated to the methodical, long-term planning required for regulatory submission.

Launching experiments without prior customer interviews or market analysis is a waste of resources. The most effective experiments are designed to answer specific questions that arise from a solid research foundation, not to substitute for it.

The old model of raising a large sum of money to build infrastructure is obsolete. Today, founders can and should validate their product and find customers with minimal capital *before* seeking significant investment, reversing the traditional order of operations.

During capital-constrained periods, founders must be ruthless in their focus. Every dollar and hour should go towards "killer experiments"—those that directly accrue value and hit the specific milestones required for the next fundraising round. "Cool science" that doesn't advance these goals is a luxury companies can't afford.

Rather than waiting for late-stage development, biotech startups should integrate commercial planning into early trials. This means building in data collection for payers, pricing, and patient access from the start. This "think with the end in mind" approach ensures the company has the right data for pivotal trials and market access.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

Moving technology from academia to a startup requires a crucial mindset shift. The academic goal of publishing data must be replaced by the industry requirement of extensive validation. For Vivtex, this single piece of advice added years of work but was essential for creating a commercially viable platform.

In biotech, early data is often ambiguous. Instead of judging programs on potential, leaders must prioritize based on the time and capital required to reach a clear 'yes' or 'no' outcome. Indefinite 'gray zone' projects drain resources that could fund a winner.

For deep tech startups aiming for commercialization, validating market pull isn't a downstream activity—it's a prerequisite. Spending years in a lab without first identifying a specific customer group and the critical goal they are blocked from achieving is an enormous, avoidable risk.